PHB: A Potential Drug Target for Cancer (P44567)

Target Name: Prohibitin

NCBI ID: P44567

Prohibitin

Other Name(s): PHB

PHB: A Potential Drug Target for Cancer

Prohibitin (PHB) is a protein that is expressed in various tissues throughout the body. It is a member of the Prohibitin superfamily (Prohibitin-Like 1), which includes proteins that share similar structural features and functions. One of the unique features of PHB is its ability to inhibit the activity of various enzymes, including DNA polymerases, which are involved in DNA replication and repair. This property makes PHB an attractive drug target, and it is the focus of ongoing research at the laboratory of Dr. in City, State.

PHB has been shown to play a critical role in the regulation of DNA replication and gene expression. In fact, PHB has been shown to interact with DNA-protein complexes, including the complex responsible for replicating DNA in the nucleus of eukaryotic cells. This interaction between PHB and DNA-protein complexes may provide a target for drugs that are designed to inhibit DNA replication and gene expression.

Another unique property of PHB is its ability to inhibit the activity of DNA polymerases. DNA polymerases are enzymes that use the template RNA to synthesize a new DNA strand. In the context of cancer, these enzymes can be used to repair damaged DNA, leading to the development of cancer. By inhibiting the activity of DNA polymerases, PHB has been shown to have a negative impact on cancer growth and the development of cancer.

In addition to its role in regulating DNA replication and gene expression, PHB has also been shown to play a role in the regulation of cell signaling pathways. For example, PHB has been shown to interact with the protein kinase kinase (PKI) kinase, which is involved in cell signaling pathways. This interaction between PHB and PKI may provide a target for drugs that are designed to inhibit cell signaling pathways.

Despite the potential benefits of targeting PHB, there are also concerns about the potential side effects of such treatments. For example, inhibiting DNA replication and gene expression can have negative impacts on the growth and development of cells, which could lead to the development of cancer . Additionally, the use of drugs that inhibit cell signaling pathways has been shown to have negative impacts on the development of certain types of cancer.

Overall, the unique properties of PHB make it an attractive drug target. Further research is needed to fully understand the role of PHB in the regulation of DNA replication and gene expression, as well as its potential as a cancer drug. By investigating the use of drugs that target PHB, researchers may be able to develop new treatments for cancer and other diseases.

Protein Name: Prohibitin (nonspecified Subtype)

The "Prohibitin Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Prohibitin comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets